Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAMBRIA-1: camizestrant versus standard extended endocrine therapy in ER-positive/HER2-negative early breast cancer
CTR20231633Phase 3Active
- Sponsor
- AstraZeneca
- Start
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of camizestrant in breast cancer (2 arms), sponsored by AstraZeneca. Primary endpoint: Invasive breast cancer-free survival. Started Nov 2023; status: active.
02
Drugs
camizestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on CTR20231633.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20231633.